Long non-coding RNAs in osteosarcoma
Metrics: PDF 2285 views | HTML 2186 views | ?
Ruiling Chen1,*, Gangyang Wang1,*, Ying Zheng1, Yingqi Hua1 and Zhengdong Cai1
1 Department of Orthopaedics, Shanghai Bone Tumor Institute, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
* These authors have contributed equally to this work
Zhengdong Cai, email:
Yingqi Hua, email:
Keywords: osteosarcoma; lncRNA; pathogenesis; biomarkers; therapeutic targets
Received: October 12, 2016 Accepted: January 09, 2017 Published: January 18, 2017
Long non-coding RNAs (lncRNAs) with more than 200 nuleotides, have been explored to participate in various cancer types including osteosarcoma (OS), which is the most common kind of primary bone tumors with high morbidity in infants and adolescents. These oncogenic or tumor suppressive lncRNAs regulate OS pathogenesis, such as cell growth, proliferation, invasion, migration, metastasis and cell apoptosis, serve as independent prognostic biomarkers or play a significant role in multidrug resistance (MDR) in OS cells. In this review, we attempt to dissect the participation of lncRNAs in pathogenesis of OS and their potential clinical values, and also provide an outlook for viable biomarkers and therapeutic targets in OS.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.